Encephalopathy has also been observed with the use of the JAK2 inhibitor fedratinib for MF: four cases (2%) of confirmed or suspected Wernicke encephalopathy were observed in the phase 3 JAKARTA trial in patients treated with fedratinib 500 mg/d [53]. The gene discussed is JAK2; the disease is mycosis fungoides.